CTMX (CytomX Therapeutics) Moat Score: 5/10 (As of Jun. 26, 2026)


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.38
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Moat Score?

CytomX Therapeutics CTMX +3.66% 36 Moat Score is 5 as of Jun. 26, 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, CytomX Therapeutics ranks better than 96.72% on this metric.

CytomX Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

CytomX Therapeutics has Narrow Moat: CytomX Therapeutics Inc has a solid narrow moat due to its valuable intellectual property and focus on innovation in the biopharmaceutical sector. The company benefits from moderate customer switching costs and a strong R&D capability, but lacks the scale and brand strength for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CytomX Therapeutics might have Narrow Moat - Solid narrow moat.

CytomX Therapeutics  (NAS:CTMX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CytomX Therapeutics Moat Score Related Terms

CTMX vs SMNR, AURA, OMER: Moat Score Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Moat Score falls into.


CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
CytomX Therapeutics (CTMX) has a Moat Score of 5 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CytomX Therapeutics ranks #46 out of 1404 companies in the Biotechnology industry, placing it in the top 3.3%.
Is CytomX Therapeutics' Moat Score too high?
CytomX Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. CytomX Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #46 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Moat Score compare to SMNR and AURA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #46 out of 1404 companies for Moat Score. This places CytomX Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. CytomX Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.38 — trading 1107.1% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Moat Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.38 is trading 1107.1% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Moat Score: 5
  • GF Value™: $0.28 vs. price of $3.38 (1107.1% above fair value)
  • GF Score™: 36/100 with 4 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1404)

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38
Price
$0.28
GF Value